Hemostatic Disorders
Welcome,         Profile    Billing    Logout  
 195 Companies   327 Products   327 Products   167 Mechanisms of Action   13 Trials   3266 News 


«12...56789101112131415...6768»
  • ||||||||||  Enrollment change, Trial withdrawal:  Single Incision Versus Standard Laparoscopic Splenectomy (clinicaltrials.gov) -  Feb 3, 2017   
    P=N/A,  N=0, Withdrawn, 
    No longer recruiting --> Completed N=30 --> 0 | Active, not recruiting --> Withdrawn
  • ||||||||||  Promacta (eltrombopag) / Novartis
    Enrollment closed, Enrollment change, Trial primary completion date:  Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients (clinicaltrials.gov) -  Feb 2, 2017   
    P2,  N=19, Active, not recruiting, 
    Active, not recruiting --> Terminated; slow accrual Recruiting --> Active, not recruiting | N=50 --> 19 | Trial primary completion date: Jun 2013 --> May 2019
  • ||||||||||  Promacta (eltrombopag) / Novartis
    Trial completion, Trial initiation date, Trial primary completion date:  Eltrombopag and the Bcl-extra-large (xL) Pathway in Idiopathic Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) -  Feb 2, 2017   
    P2,  N=12, Completed, 
    Recruiting --> Active, not recruiting | N=50 --> 19 | Trial primary completion date: Jun 2013 --> May 2019 Active, not recruiting --> Completed | Initiation date: May 2009 --> Jan 2009 | Trial primary completion date: Jan 2014 --> Sep 2015
  • ||||||||||  Promacta (eltrombopag) / Novartis
    Trial primary completion date:  End of EXTEND: Discontinuation of Medication for Patients With Immune Thrombocytopenia (clinicaltrials.gov) -  Feb 2, 2017   
    P=N/A,  N=20, Recruiting, 
    Active, not recruiting --> Completed | Initiation date: May 2009 --> Jan 2009 | Trial primary completion date: Jan 2014 --> Sep 2015 Trial primary completion date: Jun 2013 --> Mar 2019
  • ||||||||||  tranexamic acid oral / Generic mfg.
    Trial completion, Enrollment change, Trial initiation date, Trial primary completion date:  The Assessment of Tranexamic Acid in Women With Menorrhagia Who Have Bleeding Disorders (clinicaltrials.gov) -  Jan 31, 2017   
    P4,  N=249, Completed, 
    Trial primary completion date: Dec 2016 --> Apr 2017 Not yet recruiting --> Completed | N=149 --> 249 | Initiation date: Jun 2009 --> Oct 2009 | Trial primary completion date: Jun 2010 --> Mar 2014
  • ||||||||||  RiaSTAP (fibrinogen concentrate (human)) / CSL Behring
    Trial completion, Surgery:  Fibrinogen as an Alternative to FFP in Aortic Surgery. (clinicaltrials.gov) -  Jan 31, 2017   
    P4,  N=20, Completed, 
    Trial primary completion date: Dec 2016 --> Dec 2018 Recruiting --> Completed
  • ||||||||||  rocilinostat (ACY-1215) / Regenacy
    Trial completion, Trial primary completion date, Combination therapy, Monotherapy:  Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma (clinicaltrials.gov) -  Jan 24, 2017   
    P1/2,  N=120, Completed, 
    Trial primary completion date: Dec 2016 --> Nov 2017 Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Dec 2016
  • ||||||||||  Xyntha (moroctocog alfa) / Pfizer
    Enrollment closed, Trial primary completion date, Adverse events:  Study Evaluating Pharmacovigilance Of Refacto AF (clinicaltrials.gov) -  Jan 24, 2017   
    P=N/A,  N=140, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Dec 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2017 --> Oct 2016
  • ||||||||||  bortezomib / Generic mfg., pegylated liposomal doxorubicin / Generic mfg., bendamustine / Generic mfg.
    Trial primary completion date, Combination therapy:  Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma (clinicaltrials.gov) -  Jan 23, 2017   
    P1/2,  N=69, Active, not recruiting, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2017 --> Oct 2016 Trial primary completion date: Dec 2016 --> Jun 2017
  • ||||||||||  Clinical:  UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD Combination (clinicaltrials.gov) -  Jan 23, 2017   
    P2,  N=0, Withdrawn, 
    Trial primary completion date: Dec 2016 --> Dec 2017 N=30 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2018 --> Jan 2017
  • ||||||||||  aspirin / Generic mfg., hydroxyurea / Generic mfg.
    Trial completion, Trial primary completion date:  Primary Thrombocythaemia 1 Trial (clinicaltrials.gov) -  Jan 18, 2017   
    P=N/A,  N=1398, Completed, 
    Active, not recruiting --> Completed | Trial primary completion date: Nov 2015 --> Aug 2014 Active, not recruiting --> Completed | Trial primary completion date: Apr 2024 --> Nov 2016
  • ||||||||||  Jakafi (ruxolitinib) / Novartis, Incyte
    Enrollment closed, Enrollment change:  Ruxolitinib Prior to Transplant in Patients With Myelofibrosis (clinicaltrials.gov) -  Jan 18, 2017   
    P2,  N=21, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial primary completion date: Apr 2024 --> Nov 2016 Recruiting --> Active, not recruiting | N=86 --> 21
  • ||||||||||  bortezomib / Generic mfg.
    Trial completion, Enrollment change, Trial primary completion date:  UARK 2010-35, A Study of Expanded Natural Killer Cell Therapy for Multiple Myeloma (clinicaltrials.gov) -  Jan 13, 2017   
    P2,  N=10, Completed, 
    Recruiting --> Active, not recruiting | N=53 --> 40 | Trial primary completion date: Feb 2017 --> Sep 2018 Recruiting --> Completed | N=30 --> 10 | Trial primary completion date: Dec 2017 --> Oct 2016
  • ||||||||||  NovoSeven (eptacog alfa) / Novo Nordisk
    Trial completion, Surgery:  Use of Activated Recombinant FVII in Spinal Surgery (clinicaltrials.gov) -  Jan 12, 2017   
    P2,  N=50, Completed, 
    Recruiting --> Completed | N=30 --> 10 | Trial primary completion date: Dec 2017 --> Oct 2016 No longer recruiting --> Completed
  • ||||||||||  lenalidomide / Generic mfg.
    Enrollment change, Trial termination, Trial primary completion date:  Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide) (clinicaltrials.gov) -  Jan 12, 2017   
    P=N/A,  N=176, Terminated, 
    Trial primary completion date: Dec 2016 --> Oct 2015 N=300 --> 176 | Recruiting --> Terminated | Trial primary completion date: Nov 2016 --> Jul 2016; Business Decision
  • ||||||||||  Phase classification:  MRA With Feraheme in HHT (clinicaltrials.gov) -  Jan 12, 2017   
    P1,  N=10, Recruiting, 
    N=300 --> 176 | Recruiting --> Terminated | Trial primary completion date: Nov 2016 --> Jul 2016; Business Decision Phase classification: P=N/A --> P1
  • ||||||||||  NovoSeven (eptacog alfa) / Novo Nordisk
    Trial completion:  Trial of NovoSeven (clinicaltrials.gov) -  Jan 11, 2017   
    P4,  N=42, Completed, 
    Recruiting --> Active, not recruiting | N=300 --> 168 | Trial primary completion date: Jun 2024 --> Jun 2017 Recruiting --> Completed